eMedicine Specialties > Physical Medicine and Rehabilitation > Disorders of the Motor Unit

Hereditary Spastic Paraplegia: Treatment & Medication

Author: Nam-Jong Paik, MD, PhD, Chief, Associate Professor of Rehabilitation Medicine, Rehabilitation Medicine, Seoul National University Bundang Hospital
Coauthor(s): Jae-Young Lim, MD, Assistant Professor, Department of Rehabilitation Medicine, Division of Musculoskeletal Rehabilitation, Bundang Hospital, Seoul National University College of Medicine
Contributor Information and Disclosures

Updated: Jul 29, 2008

Treatment

Rehabilitation Program

Physical Therapy

Regular physical therapy (PT) is important for maintaining and improving range of motion (ROM) and muscle strength. Furthermore, PT is necessary to maintain aerobic conditioning of the cardiovascular system. Although PT does not reduce the degenerative process within the spinal cord, individuals with HSP must maintain an exercise regimen performed at least several times each week, as guided by their physical therapist. Exercise can help the patient to retain or improve muscle strength, minimize atrophy of the muscles caused by disuse, increase endurance, reduce fatigue, prevent spasms and cramps, and maintain or improve ROM. Exercise also has a positive psychological effect, helping to reduce stress and produce feelings of well-being.

Patients with HSP may experience spasticity and weakness (ie, increased muscle tone and reduced muscle strength). Because of the increased resistance to passive stretching, spasticity may make it difficult for patients to exercise certain muscles. Antispasmodic drugs may help the patient to reduce the spasticity and may allow weakened muscles to be targeted in order to improve the effectiveness of PT.

Different types of exercised incorporated into PT programs for patients with HSP may include strengthening, stretching, and aerobic exercises, as follows:

  • Strengthening exercises - These help to strengthen muscles that have not yet weakened. Strengthened muscles help to compensate for muscles that have weakened, decreasing the rate of functional impairment. Exercise may also help to slow the development of disuse atrophy, which occurs in muscles that are not being used (eg, in calf muscles of people who use wheelchairs). Back-strengthening exercises may help to reduce or eliminate back pain associated with HSP. Such pain is probably not due to HSP itself but to strain on the back resulting from HSP (eg, poor gait, poor posture, use of a mobility device).
  • Stretching exercises - These help to maintain or increase ROM and to reduce such problems as tendinitis, bursitis, and muscle cramps.
  • Aerobic exercises - These improve cardiovascular fitness, reduce fatigue, and increase endurance and general fitness. Walking, bicycle riding, water aerobics, and swimming are among many excellent forms of aerobic exercise.

Medical Issues/Complications

Currently, no specific treatment exists to prevent, retard, or reverse progressive disability in patients with HSP. Nonetheless, treatment approaches used for chronic paraplegia from other causes are useful.

Possible complications associated with HSP include the following:

  • Gastrocnemius-soleus contracture
    • This condition is more common when symptoms begin in childhood rather than in adulthood.
    • It also occurs when PT has not been sufficient.
  • Cold feet
    • Many people with HSP complain of cold feet. This is a common complaint in many disorders of the upper or lower motor neurons.
    • Cold feet may be related to abnormal thermoregulation of cutaneous vessels; however, circulation is usually preserved.
  • Fatigue
    • Fatigue is a common symptom of HSP. One obvious cause is the extra effort required for walking, because of muscle weakness in the legs.
    • Various medications prescribed for HSP cause drowsiness or fatigue. Many patients with HSP may not get their required amount sleep, because of leg cramps or spasms or as a result of the frequent need to urinate during the night.
    • A less obvious cause of fatigue may be the fact that because of a more sedentary lifestyle, people with HSP often are not aerobically fit and therefore have reduced endurance. Stress or depression also can contribute to fatigue.
  • Back or knee pain
    • Back and/or knee pain is common in people with HSP. The pain is not directly due to HSP itself but is instead often caused by muscle weakness and gait abnormalities resulting from HSP.
    • As certain muscles become weaker, other muscles need to compensate for that weakness. Compensatory measures create an awkward gait that causes strain on many muscles and joints.
    • Patients may thrust their shoulders back or swing their legs outward as they walk. Use of certain mobility devices also may put a strain on the arms or back.
  • Stress and depression
    • Stress, depression, and denial are not unusual in patients with HSP or any other chronic illness.
    • Denial is not necessarily a problem, as long as the person in denial is not depriving himself or herself of proper treatment and care. Denial allows some people to cope and set their worries aside.
    • Some people with HSP face denial by family members who refuse to admit that a problem exists. This can create a frustrating and stressful situation.

Consultations

  • Physical medicine and rehabilitation specialist
  • Neurologist

Medication

The goals of pharmacotherapy are to reduce morbidity and prevent complications.6

Antispasmodics

Bladder spasticity has been improved with oxybutynin (Ditropan).


Oxybutynin (Ditropan)

Inhibits the action of acetylcholine on smooth muscle and has a direct antispasmodic effect on smooth muscle. This in turn causes an increase in bladder capacity and a decrease in uninhibited contractions.

Adult

5 mg PO bid/tid; not to exceed 5 mg qid

Pediatric

<5 years: Not established
>5 years: 5 mg PO bid/tid

CNS effects increase with concurrent CNS depressants

Documented hypersensitivity; glaucoma, partial or complete GI obstruction, myasthenia gravis, ulcerative colitis and toxic megacolon

Pregnancy

B - Fetal risk not confirmed in studies in humans but has been shown in some studies in animals

Precautions

Caution in urinary tract obstruction, reflux esophagitis, and heart disease

Skeletal muscle relaxants

Antispasticity medications can be useful. However, one of the drawbacks of using these agents is that some patients find that the stiffness of spasticity helps them to overcome the muscle weakness that also occurs in HSP. When patients are medicated to reduce stiffness, walking may become more difficult. Adverse effects can also be a problem. If the patient does well with the medications, however, discomfort associated with spasticity can generally be reduced, mobility can be improved, and the effectiveness of PT can be enhanced. Patients in relatively early stages of the illness have achieved symptomatic improvement with oral dantrolene, as well as with oral and intrathecal baclofen.


Baclofen (Lioresal)

May induce the hyperpolarization of afferent terminals and inhibit monosynaptic and polysynaptic reflexes at the spinal level.

Adult

Initially: 5 mg tid, increase 15 mg/d with tid every 3 d
Maintain: 30-80 mg/d (max dose: 100-120 mg/d)

Pediatric

12-24 months: 10-20 mg/d
2-10 years: 30-60 mg/d
>10 years: maximal 2.5 mg/kg/d

Opiate analgesics, benzodiazepines, alcohol, tricyclic antidepressants, guanabenz, MAOIs, clindamycin, and hypertensive agents may increase effects

Pregnancy

C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus

Precautions

Caution in history of autonomic dysreflexia and when spasticity is used to increase function; autonomic dysreflexia can result from withdrawal of this medication


Tizanidine (Zanaflex)

Centrally acting muscle relaxant metabolized in the liver and excreted in urine and feces. A single oral dose of 8 mg reduces muscle tone in patients with spasticity for several hours. Blood levels and the spasmolytic effect are linearly correlated.

Adult

4-8 mg PO q8h prn; not to exceed 36 mg/d

Pediatric

Not established

May interact with alcohol (increasing somnolence, stupor) and oral contraceptives (decreasing clearance); possible increased hypotensive effects with concurrent diuretics

Pregnancy

C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus

Precautions

Caution in renal impairment


Dantrolene sodium (Dantrium, Dantrium IV)

Stimulates muscle relaxation by modulating skeletal muscle contractions at the site beyond the myoneural junction and acting directly on muscle itself. Most patients respond to 400 mg/d or less.

Adult

Initially: 25 mg qd
Increase: 25-100 mg bid/qid (max dose: 200 mg qid)

Pediatric

Initially: 1 mg/kg qd
Increase: 0.5-3.0 mg/kg bid/qid (max dose: 100 mg qid)
<5 years: Safety not established

Coadministration of clofibrate and warfarin may increase toxicity; coadministration with estrogen may increase hepatotoxicity in women >35 y

Documented hypersensitivity; active hepatic disease (hepatitis and cirrhosis)

Pregnancy

C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus

Precautions

May cause hepatotoxicity (use only for recommended indications); caution in impaired pulmonary function and severe cardiac insufficiency; may cause photosensitivity with exposure to sunlight


Botulinum toxin (BOTOX®)

Binds to receptor sites on motor nerve terminals and inhibits the release of acetylcholine, which in turn inhibits the transmission of impulses in neuromuscular tissue. This agent is most useful for treating spasticity in the gastrocnemius and soleus muscles; it is less effective in larger muscles (eg, quadriceps). Reexamine patients 7-14 d after the initial dose to assess for their response. May be repeated q3-4 mo.

Adult

5-100 U depending on muscle affected and injection technique; not to exceed 300-400 U/treatment session

Pediatric

<12 years: Not established
>12 years: Administer as in adults

Aminoglycosides or drugs that interfere with neuromuscular transmission may potentiate effects of botulinum toxin

Pregnancy

C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus

Precautions

Do not exceed recommended dosages and frequencies of administration; presence of antibodies to botulinum toxin type A may reduce effects of therapy

Benzodiazepines

These agents may act in the spinal cord to induce muscle relaxation.


Diazepam (Valium)

Depresses all levels of CNS (eg, limbic and reticular formation), possibly by increasing the activity of GABA.
Individualize the dosage and increase it cautiously to avoid adverse effects.

Adult

Mild spasms: 5-10 mg PO q4-6h prn
Moderate spasms: 5-10 mg IV prn
Severe spasms: Mix 50-100 mg in 500 mL D5W and infuse at 40 mL/h

Pediatric

Mild spasms: 0.1-0.8 mg/kg/d PO divided tid/qid
Moderate or severe spasms: 0.1-0.3 mg/kg IV q4-8h

Increases toxicity of benzodiazepines in CNS with coadministration of phenothiazines, barbiturates, alcohols, and MAOIs

Documented hypersensitivity; narrow-angle glaucoma

Pregnancy

C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus

Precautions

Caution with other CNS depressants, low albumin levels, or hepatic disease (may increase toxicity)

More on Hereditary Spastic Paraplegia

Overview: Hereditary Spastic Paraplegia
Differential Diagnoses & Workup: Hereditary Spastic Paraplegia
Treatment & Medication: Hereditary Spastic Paraplegia
Follow-up: Hereditary Spastic Paraplegia
Multimedia: Hereditary Spastic Paraplegia
References

References

  1. Sawhney IM, Bansal SK, Upadhyay PK, et al. Evoked potentials in hereditary spastic paraplegia. Ital J Neurol Sci. Sep 1993;14(6):425-8. [Medline].

  2. Reid E. Pure hereditary spastic paraplegia. J Med Genet. Jun 1997;34(6):499-503. [Medline][Full Text].

  3. Appleton RE, Farrell K, Dunn HG. 'Pure' and 'complicated' forms of hereditary spastic paraplegia presenting in childhood. Dev Med Child Neurol. Apr 1991;33(4):304-12. [Medline].

  4. Fink JK. Advances in the hereditary spastic paraplegias. Exp Neurol. Nov 2003;184 Suppl 1:S106-10. [Medline].

  5. Tallaksen CM, Durr A, Brice A. Recent advances in hereditary spastic paraplegia. Curr Opin Neurol. Aug 2001;14(4):457-63. [Medline].

  6. Züchner S. The genetics of hereditary spastic paraplegia and implications for drug therapy. Expert Opin Pharmacother. Jul 2007;8(10):1433-9. [Medline].

  7. Paisan-Ruiz C, Dogu O, Yilmaz A, et al. SPG11 mutations are common in familial cases of complicated hereditary spastic paraplegia. Neurology. Apr 15 2008;70(16 Pt 2):1384-9. [Medline].

  8. Hazan J, Fonknechten N, Mavel D, et al. Spastin, a new AAA protein, is altered in the most frequent form of autosomal dominant spastic paraplegia. Nat Genet. Nov 1999;23(3):296-303. [Medline].

  9. Depienne C, Stevanin G, Brice A, et al. Hereditary spastic paraplegias: an update. Curr Opin Neurol. Dec 2007;20(6):674-80. [Medline].

  10. Fink JK, Rainier S. Hereditary spastic paraplegia: spastin phenotype and function. Arch Neurol. Jun 2004;61(6):830-3. [Medline].

  11. Orlacchio A, Patrono C, Gaudiello F, et al. Silver syndrome variant of hereditary spastic paraplegia: A locus to 4p and allelism with SPG4. Neurology. May 20 2008;70(21):1959-66. [Medline].

  12. Tzoulis C, Denora PS, Santorelli FM, et al. Hereditary spastic paraplegia caused by the novel mutation 1047insC in the SPG7 gene. J Neurol. Jun 23 2008;[Medline].

  13. Fink JK, Heiman-Patterson T, Bird T, et al. Hereditary spastic paraplegia: advances in genetic research. Hereditary Spastic Paraplegia Working Group. Neurology. Jun 1996;46(6):1507-14. [Medline].

  14. Hazan J, Lamy C, Melki J, et al. Autosomal dominant familial spastic paraplegia is genetically heterogeneous and one locus maps to chromosome 14q. Nat Genet. Oct 1993;5(2):163-7. [Medline].

  15. Schady W, Smith CM. Sensory neuropathy in hereditary spastic paraplegia. J Neurol Neurosurg Psychiatry. Jun 1994;57(6):693-8. [Medline][Full Text].

  16. Schady W, Dick JP, Sheard A, et al. Central motor conduction studies in hereditary spastic paraplegia. J Neurol Neurosurg Psychiatry. Sep 1991;54(9):775-9. [Medline][Full Text].

  17. Claus D, Waddy HM, Harding AE, et al. Hereditary motor and sensory neuropathies and hereditary spastic paraplegia: a magnetic stimulation study. Ann Neurol. Jul 1990;28(1):43-9. [Medline].

Further Reading

Keywords

hereditary spastic paraplegia, HSP, hereditary spastic paraparesis, familial spastic paraparesis, Strumpell-Lorrain syndrome, Strumpell-Lorrain disease, Strümpell-Lorrain syndrome, Strümpell-Lorrain disease, pure hereditary spastic paraplegia, uncomplicated hereditary spastic paraplegia, complicated hereditary spastic paraplegia

Contributor Information and Disclosures

Author

Nam-Jong Paik, MD, PhD, Chief, Associate Professor of Rehabilitation Medicine, Rehabilitation Medicine, Seoul National University Bundang Hospital
Nam-Jong Paik, MD, PhD is a member of the following medical societies: American Association of Neuromuscular and Electrodiagnostic Medicine
Disclosure: Nothing to disclose.

Coauthor(s)

Jae-Young Lim, MD, Assistant Professor, Department of Rehabilitation Medicine, Division of Musculoskeletal Rehabilitation, Bundang Hospital, Seoul National University College of Medicine
Jae-Young Lim, MD is a member of the following medical societies: American Association of Neuromuscular and Electrodiagnostic Medicine
Disclosure: Nothing to disclose.

Medical Editor

Teresa L Massagli, MD, Residency Director, Professor, Department of Rehabilitation Medicine and Pediatrics, University of Washington School of Medicine
Teresa L Massagli, MD is a member of the following medical societies: American Academy of Pediatrics, American Academy of Physical Medicine and Rehabilitation, and Association of Academic Physiatrists
Disclosure: Nothing to disclose.

Pharmacy Editor

Francisco Talavera, PharmD, PhD, Senior Pharmacy Editor, eMedicine
Disclosure: Nothing to disclose.

Managing Editor

Kat Kolaski, MD, Assistant Professor, Departments of Orthopedic Surgery and Pediatrics, Wake Forest University School of Medicine
Kat Kolaski, MD is a member of the following medical societies: American Academy for Cerebral Palsy and Developmental Medicine and American Academy of Physical Medicine and Rehabilitation
Disclosure: Nothing to disclose.

CME Editor

Kelly L Allen, MD, Consulting Staff, Department of Physical Medicine and Rehabilitation, Lourdes Regional Rehabilitation Center, Our Lady of Lourdes Medical Center
Disclosure: Nothing to disclose.

Chief Editor

Denise I Campagnolo, MD, MS, Director of Multiple Sclerosis Clinical Research and Staff Physiatrist, Barrow Neurology Clinics, St. Joseph's Hospital and Medical Center; Investigator for Barrow Neurology Clinics; Director, NARCOMS Project for Consort
Denise I Campagnolo, MD, MS is a member of the following medical societies: Alpha Omega Alpha, American Association of Neuromuscular and Electrodiagnostic Medicine, American Paraplegia Society, Association of Academic Physiatrists, and Consortium of Multiple Sclerosis Centers
Disclosure: Teva Neuroscience Honoraria Speaking and teaching; Serono-Pfizer Honoraria Speaking and teaching

 
 
HONcode

We subscribe to the
HONcode principles of the
Health On the Net Foundation

All material on this website is protected by copyright, Copyright© 1994- by Medscape.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.